DUESSELDORF (dpa-AFX) - German drug delivery devices maker Gerresheimer AG (GRRMF.PK) Thursday said that for fiscal 2016, its expectation for Group revenues is approximately 1.5 billion euros, corresponding to between 4% and 5% organic revenue growth.
The company aims for adjusted EBITDA of some 320 million euros. Capital expenditure will be around 8% of revenues.
The company further said its medium-term indication for financial years 2016 to 2018 puts organic revenue growth at 4% to 5% a year. The EBITDA margin is set to reach 22% in financial year 2018. In order to meet these targets, Gerresheimer will require significantly lower annual capital expenditure of around 8% of revenues.
Chief Executive Officer Uwe Röhrhoff said he continues to be very optimistic for the future of Gerresheimer.
Copyright RTT News/dpa-AFX